Private Companies 28

UK

April 17, 2018: BlueGnome Limited issued new U.S. patent [9,944,987]

NEWS BITES - PRIVATE COMPANIES

BlueGnome Limited has been issued a new U.S. patent titled "Assessment of risk of aneuploidy" by the US Patent and Trademark Office.

ABSTRACT

The present disclosure relates generally to methods and materials for use in detecting abnormalities of the number of whole chromosomes or chromosome regions (aneuploidy). It has particular utility for assessing the risk of aneuploidy of eggs (i.e., oocytes), fertilized eggs or embryos developed therefrom in the context of in vitro fertilization.

Appl. No.14/760,630
PCT FiledMarch 26, 2014
PCT No.PCT/GB2014/050955

INDEX

SECTION 1 BLUEGNOME LIMITED FINANCIALS

SECTION 2 BLUEGNOME LIMITED PROFILE

SECTION 3 OTHER NEWS: 2013

SECTION 4 BLUEGNOME LIMITED PATENTS

SECTION 1 BLUEGNOME LIMITED FINANCIALS

FY2016 Annual Report: BlueGnome Limited Net Profit up 4.8%

Highlights

    Net profit of GBP6.1m ($US9.0m)

    Interest cover of 191.9

    EBIT Margin of 27.6%

    Total debt to net tangible assets of 0.2

    Total Liabilities to EBITDA of 0.7: this compares favourably with the Joseph Piotroski benchmark of <5

    Debt to Equity of 0.2

    Total liabilities to Total assets of 0.2

    Current ratio of 4.2

    Working capital to total assets of 71.8%

    EBIT to total assets of 32.9%

    Total revenue to total assets of 1.2

    Annual

    Company Name : BlueGnome Limited
    January 0320162016
    DescriptionGBP m$US m
    Sales Revenue28.241.7
    EBITDA8.312.2
    Depreciation0.50.7
    EBIT7.811.5
    Pre-Tax Profit/(Loss)7.711.4
    Profit/(Loss) after Tax6.19
    Working Capital1725.1
    Current Assets22.333
    Current Liabilities5.47.9
    Shareholders' Funds18.126.8
    Total Liabilities5.58.1
    Total Assets23.634.9
    Current Debt3.24.8
    Total Debt3.24.8
    Cash and cash equivalents10.215.1
    AuditorERNST & YOUNG LLP

    January 032016
    Performance Ratios
    Return on Equity (%)33.6
    Return on Assets (%)25.8
    Total debt to net tangible assets (%)17.8
    Total Liabilities to EBITDA0.7
    Debt/Equity0.2
    Total Liabilities/Total Assets0.2
    Interest Cover191.9
    Current Ratio4.2
    Common Size Ratios by Assets %
    Total current assets to Total Assets 94.5
    Cash to Total Assets 43.2
    Fixed Assets to Total Assets 5.5
    Total non-current assets to Total Assets 5.5
    Common Size Ratios by Sales %
    Cost of Goods Sold to Sales 50.8
    Profit before tax to Sales 27.4
    Sales and marketing expenses to Sales 14.7
    Tax expenses to Sales 5.8
    Depreciation to Sales 1.7

    Currency Conversion (January 03, 2016): $US1 = GBP0.68

    SECTION 2 BLUEGNOME LIMITED PROFILE

    2.1 ACTIVITIES

    BlueGnome Limited, a biotechnology company, provides genetic diagnostic solutions for the screening of chromosomal abnormalities in cytogenetics and IVF. The company offers solutions for the investigation of copy number imbalance in the human genome and the main application areas include analysis of pre- and post-natal samples to identify genetic abnormalities related to developmental delay, investigation of cancer samples, and aneuploidy screening of single cells in IVF. Its products include 24sure, a solution that includes whole genome amplification, optimized consumables, data analysis and management software, and a range of laboratory hardware; CytoChip Cancer that combines the precision of FISH with high resolution screening of copy number imbalance in the whole cancer genome; and CytoChip international standard cytogenetic array (ISCA) that enables laboratories to implement arrayCGH using the industry standard ISCA design. The company offers CytoChip Focus for applications where the amount of starting material falls below that required for the CytoChip ISCA; and BlueFish probes. It exports its products to major laboratories around the world. The company was incorporated in 2001 and is based in Cambridge, United Kingdom. As of September 19, 2012, BlueGnome Limited operates as a subsidiary of Illumina Inc.

    2.2 SUMMARY

    Fiscal Year End: 03 Jan 2016

    PermID: 4297696051

    Website: http://www.cambridgebluegnome.com

    SECTION 3 OTHER NEWS: 2013

    December 04: BlueGnome Limited: Christmas Dispatch 2013

    [Company Release]

    Christmas is rapidly approaching and to ensure that customers can plan their schedules over the Festive period, we have outlined the ordering and dispatch schedule below.

    To receive BlueGnome deliveries by the end of 2013, orders must be received by Friday the 13th of December

    Last UK shipment date 2013 - Thursday, 19th December

    Last European shipment date 2013 - Wednesday, 18th December

    Last US/rest of the world shipment date 2013 - Monday, 16th December

    First European shipment date 2014 - Tuesday, 7th January

    First US/rest of the world shipment date 2014 - Monday, 6th January

    For BlueFish orders please refer to this table:

    Probe type Order by noon (GMT) of Shipping date

    7 day 16th December 2013 18th December 2013

    6th January 2014 8th January 2014

    14 day 16th December 2013 8th January 2014

    6th January 2014 15th January 2014

    Source: Company Website

    SECTION 4 BLUEGNOME LIMITED PATENTS

    4.1 Previous BLUEGNOME LIMITED Patent title:

    Issue DateIssuing OfficePatent TitlePatent Number
    May 16, 2017US PTOComparative genomic hybridization array method for preimplantation genetic screening9,652,585

    4.2 Previous BLUEGNOME LIMITED Patent abstract:

    May 16, 2017 BlueGnome Limited issued new U.S. patent [9,652,585]

    ABSTRACT

    A method for determining the presence of a copy number imbalance in genomic DNA of a test sample is provided. The method can separately measure hybridization of a single test sample to a first hybridization array and hybridization of a plurality of reference samples to a plurality of other, respective test arrays. A determination of copy number can be based on the best fit reference array, relative to the test array. The best fit can be determined based on the closest or most similar signal-to-noise ratio of the measured signals.

    PermID: 4297696051

    Created by www.buysellsignals.com for News Bites Finance